Hyde IQ vs Hyde N-Bar: A Comparison of Disposable Vapes

Sep.08.2022
Hyde IQ vs Hyde N-Bar: A Comparison of Disposable Vapes
Hyde Vape offers top-tier disposable and rechargeable e-cigarettes, each with unique features such as battery indicators and flavor options.

Today, the e-cigarette industry is one of the fastest-growing industries. This is especially true as e-cigarettes have been popular in the market for a long time. Among the different varieties available, disposable e-cigarettes have become the perfect choice for users due to their portability and design. The Hyde Vape brand is one of the best brands that offers disposable e-cigarettes.

 

The two most popular choices from Hyde vape are the Hyde IQ Disposable Vape Pen 5000 Puffs and the Hyde N-Bar 4500 Puffs Rechargeable. However, these electronic cigarette devices have more or less similar functions, making it difficult to choose the better device.

 

For your convenience, we will assist you in understanding the difference between the two in this article.

 

In an attempt to differentiate between Hyde IQ and Hyde N-Bar, we have identified various parameters. We aim to provide a clearer understanding of both product categories.

 

Number of inhalations/suctions.

 

Although both of these electronic cigarette devices are among the best and most durable disposable products on the market, they differ in the number of puffs they can provide.

 

The Hyde IQ can provide an excellent vaping experience with approximately 5000 puffs from a single charge, while the Hyde N-Bar rechargeable vape lasts for about 4500 puffs.

 

Although Hyde N-Bar boasts a 4500 puff count, which is relatively high compared to other disposable e-cigarettes on the market, it falls behind Hyde IQ.

 

Therefore, in terms of maximum suction times, the Hyde IQ performs slightly better than the Hyde N-Bar.

 

Battery indicator light.

 

Regarding battery capacity and lifespan, both Hyde IQ and Hyde N-Bar have rechargeable batteries and are convenient for USB charging.

 

However, the Hyde IQ disposable Vape Pen 5000 Puffs comes equipped with a unique battery indicator light.

 

This innovative battery features indicator lights that display three signals: red when the battery is only at 1-16% capacity, orange when it is at approximately 16-30% capacity, and green when it is at 30-100% capacity.

 

For vapers, this is very convenient. Therefore, in this aspect, Hyde IQ is stealing the show with its innovation.

 

Electronic cigarette liquid or e-liquid.

 

When comparing disposable electronic cigarettes, one important factor to consider is the e-liquid. This type of liquid is contained in various cartridges and contains propylene glycol and nicotine.

 

The Hyde N Bar 4500 Puffs is a rechargeable vape with a pre-filled electronic liquid capacity of 10 milliliters. The liquid contains approximately 5% nicotine.

 

Alternatively, the Hyde IQ comes with a vape juice capacity of 8 milliliters. However, its nicotine content is similar to that of the Hyde N-Bar, at 5%.

 

Therefore, the nominal edge of Hyde N-Bar in terms of e-liquid is approximately 2 milliliters.

 

However, despite the difference in the amount of e-liquid between the two, Hyde IQ produces more puffs and lasts for 1-2 days longer. Therefore, it is clear that the efficiency of Hyde N-Bar is lower than that of Hyde IQ.

 

When it comes to popular choices in e-cigarettes, both Hyde IQ and Hyde N Bar offer a variety of flavors.

 

The Hyde IQ disposable Vape Pen 5000 comes in 20 different flavors including watermelon soda, cranberry orange soda, pink burst, and lemon drop. Each flavor is unique and exciting.

 

On the other hand, Hyde N-Bar offers over 20 flavors including popular choices such as aloe grape, banana and cream, minty O's, peach mango watermelon, Caribbean cola, and tropical flavors.

 

Therefore, in terms of taste, both electronic cigarette devices are comparable.

 

Conclusion

 

The Hyde IQ disposable Vape Pen with 5000 puffs and the Hyde N-Bar 4500 Puffs Rechargeable Vape are two of the best disposable e-cigarettes available in the market. While we have highlighted some distinguishing parameters, it is ultimately up to you to make the best judgment.

 

Statement:

 

This article is compiled from third-party information and is only intended for industry-related communication and learning purposes.

 

This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article's content. The translation of this article is intended only for industry-related exchange and research purposes.

 

Due to limitations in translation ability, the article may not fully express the same meaning as the original. Please refer to the original article for accuracy.

 

2FIRSTS aligns fully with the Chinese government when it comes to any domestic, Hong Kong, Macau, Taiwan, or foreign related statements and positions.

 

The compilation of information is the copyright of the original media and author. If there is any infringement, please contact us for removal.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia Adds 6-Methylnicotine to Schedule 9 Prohibited Substances, Effective October 1
Australia's Therapeutic Goods Administration published a final decision on September 25 to classify 6-methylnicotine as a Schedule 9 prohibited substance under the Poisons Standard, effective October 1, 2026. TGA said the chemical has been reported in e-cigarette liquids sold in Australia and marketed as nicotine-free or nicotine alternatives, while evidence also indicates its use in preparations such as oral pouches. The government originally proposed a Schedule 7 classification but ultimately adopted the stricter Schedule 9 designation, citing acute toxicity, dependence risk, use in unapproved consumer products and misleading marketing.
News
Sep.29 by 2Firsts Perspectives
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
Product | VAPORESSO Launches PRIX MTL Pod, With NFC Version Linking Interchangeable Panels to On-Screen Animations
VAPORESSO introduced the PRIX MTL pod system in August 2026 in two versions, Filter and NFC. The Filter version allows users to switch between a conventional drip tip and a filter tip, while the NFC version links interchangeable panels to matching on-screen animations. PRIX features a 2,600mAh battery, a 5.5ml pod, a 0.87-inch TFT display and a maximum output of 40W, alongside Dual Mesh Impact Pods capable of operating at two resistance and power configurations. VAPORESSO's French website lists MSRP at $39.99 for the Filter version and $49.90 for the NFC version.
Market
Aug.24 by 2Firsts Perspectives
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
JUUL2 Sued Within a Week of FDA Authorization as AJ Marketing Alleges Infringement of Programmable Vape Patent
Less than a week after JUUL2 received U.S. FDA marketing authorization on August 28, 2026, JUUL Labs was sued for patent infringement in federal court in Delaware. AJ Marketing LLC filed the complaint on September 3, alleging that both JUUL 1 and JUUL2 infringe U.S. Patent No. 8,851,068 B2. The patent covers aspects of programmable electronic vaporization devices, including controls over dose delivery, usage frequency and operating parameters. The plaintiff is seeking reasonable royalties and ongoing royalties tied to the remaining life of the patent. JUUL has not yet publicly responded to the case.
Sep.10
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08